Health Care & Life Sciences » Pharmaceuticals | Alvogen Korea Co. Ltd.

Alvogen Korea Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
70,833
65,262
165,837
181,183
190,057
Cost of Goods Sold (COGS) incl. D&A
30,699
36,303
69,618
81,968
102,152
Gross Income
40,134
28,959
96,219
99,215
87,905
SG&A Expense
34,621
39,890
75,302
68,245
61,645
EBIT
4,993
11,351
20,689
30,730
25,962
Unusual Expense
-
1,977
2,870
18,615
3,844
Non Operating Income/Expense
957
1,130
4,207
4,550
1,944
Interest Expense
334
637
5,607
4,643
7,567
Pretax Income
6,742
11,823
17,036
12,575
17,048
Income Tax
4,715
1,136
4,796
3,898
6,649
Consolidated Net Income
2,026
10,687
12,240
8,677
10,399
Net Income
2,026
10,687
12,240
8,677
10,399
Net Income After Extraordinaries
2,026
10,687
12,240
8,677
10,399
Net Income Available to Common
2,026
10,687
12,240
8,677
10,399
EPS (Basic)
414.00
2,057.00
1,032.00
732.00
909.00
Basic Shares Outstanding
5
5
12
12
11
EPS (Diluted)
414.34
2,057.01
1,032.20
731.78
909.39
Diluted Shares Outstanding
5
5
12
12
11
EBITDA
7,253
8,358
25,853
36,865
32,646
Other Operating Expense
519
421
228
239
298
Non-Operating Interest Income
1,126
1,012
618
553
553

About Alvogen Korea Co.

View Profile
Address
13/F, IFC Two
Seoul SL 07241
Korea, Republic Of
Employees -
Website http://www.Alvogenkorea.com
Updated 09/14/2018
Alvogen Korea Co., Ltd. engages in the manufacture of pharmaceutical products. It offers products for the therapeutic areas of endocrine system, urinary system, neuropsychiatry system, anti-inflammatory, antipyretic, analgesic, gastrointestinal system, cardiovascular system, dermatology, hepatitis, antibiotics, respiratory system, hormones etc. It provides pharmaceutical products in various dosage forms, including tablets, capsules, granules, powders, ampoules, vials and intravenous (IV) solutions.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.